


FIGURE 1A



E2 6K-E1
SVGmu IPTSLALLCCVRSANAETFTETMSYLWSNSQPFFWVQLCIPLAAFIVLMRCCSCCLPFLVVAGAYLAKVDAYEHATTVPN
SIN-Var1
SIN-Var2
SIN-Var3
SVGmu VPQIPYKALVERAGYAPLNLEITVMSSEVLPSTNQEYITCKFTTVVPSPKIKCCGSLECQPAAHAGYTCKVFGGVYPFMW
SIN-Var1 D
SIN-Var2 D
SIN-Var3 D
SVGmu GGAQCFCDSENSQMSEAYVELSADCASDHAQAIKVHTAAMKVGLRIVYGNTTSFLDVYVNGVTPGTSKDLKVIAGPISAS
SIN-Var1
SIN-Var2
SIN-Var3
SVGmu FTFFDHKVVIHRGLVYNYDFPEYGAMKPGAFGDIQATSLTSKDLIASTDIRLLKPSAKNVHVPYTQASSGFEMWKHNSGR
SIN-Var1
SIN-Var2
SIN-Var3
SVGmu PLQETAPFGCKIAVNPLRAVDCSYGNIPISIDIPNAAFIRTSDAPLVSTVKCEVSECTYSADFGGMATLQYVSDREGQCP
SIN-Var1
SIN-Var2
SIN-Var3
SVGmu VHSHSSTATLQESTVHVLEKGAVTVHFSTASPQANFIVSLCGKKTTCNAECKPPADHIVSTPHKNDQEFQAAISKTSWSW
SIN-Var1
SIN-Var2
SIN-Var3
SVGmu LEALFGGASSLLIIGLMIFACSMMLTSTRR*
SIN-Var1 **
SIN-Var2 **
SIN-Var3 **

FIGURE 1B



Self-inactivating (SIN) vector
5' CMV LTR
CMV
Ψ+
SD
HIV-1 RRE
cPPT
SA
UbiC
ANTIGEN
WPRE
3' SIN LTR
Third generation LV packaging plasmids
RSV
REV
polyA
CMV
Gag
Pol
HIV-1 RRE
polyA
Dendritic cell targeting envelope
CMV
SINV glycoproteins
polyA

FIGURE 2



10^6
10^5
10^4
GFU/mL
SVGmu
Sin-HR
Sin-Var1
SIN-Var1
SIN-Var2
SIN-Var3

FIGURE 3



% H-2K^b/OVA$_{257}$ multimer$^+$
% IFN-γ$^+$
IFN-γ$^+$ IL-2$^+$ TNF-α$^+$
IFN-γ$^+$ IL-2$^+$ TNF-α$^+$
IFN-γ$^+$ IL-2$^-$ TNF-α$^+$
IFN-γ$^+$ IL-2$^-$ TNF-α$^-$
10
1
0.1
SinVar1
SinVar2
SinVar3
vehicle
2500 ng
125 ng

FIGURE 4A



SinVar1
SVGmu
HBSS
0
10
200
4000
p24 dose (ng)
% H-2K^b/OVA$_{257}$$^+$
10
8
6
4
2
0

FIGURE 4B




SinVar1
SVGmu
vehicle
% IFN-γ+
0
2
4
6
0
2
15
102
714
5000
p24 dose (ng)

FIGURE 4C



Vector Construct Name	Designation
SIN	*SIN/PPT+*
703	*EXT/PPT+*
704	*EXT/PPT-*

FIGURE 5A




FIGURE 5B




FIGURE 6B




FIGURE 6A



SIN/IN+
SIN/IN-
703/IN+
703/IN-
704/IN+
704/IN-
140%
120%
100%
80%
60%
40%
20%
0%
Relative Titer (GFU/mL)
1
2
3
4
5
Passage

FIGURE 7



IFN-γ+ IL-2- TNF-α-
IFN-γ+ IL-2- TNF-α+
IFN-γ+ IL-2+ TNF-α+
IFN-γ+ IL-2+ TNF-α-
vehicle
Int^D64V
Int^wt
0
1
2
3
% of CD8

FIGURE 8



DC-NILV
vehicle
Tumor Size (mm²)
Days Post Challenge
Percent survival
Days Post Challenge

FIGURE 9